Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Gadoquatrane 0.03 mmol Gd/kg · 1 trial · 2 indications
Including severity of TEAE
| Arm | Type | Description |
|---|---|---|
| 0.03 mmol Gd/kg BAY1747846 and matching placebo | EXPERIMENTAL | 12 healthy male participants were planned to be enrolled into this arm, 9 on BAY1747846 and 3 on placebo |
| 0.1 mmol Gd/kg BAY1747846 and matching placebo | EXPERIMENTAL | 12 healthy male participants were planned to be enrolled into this arm, 9 on BAY1747846 and 3 on placebo |
| Name | Type | Description |
|---|---|---|
| Gadoquatrane (BAY1747846) 0.03 mmol Gd/kg | DRUG | 0.03 mmol Gd/kg by intravenous injection (at 2 mL/s) |
| Gadoquatrane (BAY1747846) 0.1 mmol Gd/kg | DRUG | 0.1 mmol Gd/kg by intravenous injection (at 2 mL/s) |
| Matching placebo | DRUG | 0.9% sodium chloride by intravenous injection (at 2 mL/s) |
Inclusion Criteria: * Signed informed consent prior to any study specific tests or procedures * Chinese male between 18 and 45 years (inclusive) at screening visit * Body mass index (BMI): 18.5 to 30.0 kg/m² (inclusive) * Body weight (bw): 50 to 90 kg (inclusive) * Participants of reproductive pote...
Gadoquatrane 0.03 mmol Gd/kg is an investigational small molecule being developed by Bayer AG as a contrast agent for magnetic resonance imaging (MRI). The 0.03 mmol Gd/kg refers to the gadolinium dose level studied. It is designed to enhance contrast during MRI scans, helping to improve visualization of internal structures.
Gadoquatrane 0.03 mmol Gd/kg is being studied for contrast enhancement in magnetic resonance imaging. It is intended to improve the visibility of tissues and structures during MRI procedures. The clinical program has evaluated it in healthy male volunteers rather than in patients with a specific disease.
Gadoquatrane 0.03 mmol Gd/kg is being developed by Bayer AG, which trades under the ticker BAYRY. Bayer is the sponsor of the clinical program for this MRI contrast agent candidate.
Gadoquatrane 0.03 mmol Gd/kg is in Phase 1 clinical development. It is an investigational agent and has not been approved by the FDA. The completed Phase 1 trial evaluated single ascending doses in healthy Chinese male participants.
Gadoquatrane 0.03 mmol Gd/kg has been studied in one completed Phase 1 trial, NCT06135181. That trial enrolled 24 healthy Chinese male participants aged 18 years and older and assessed safety and blood levels of BAY1747846 after single intravenous doses. It was randomized and controlled.
Yes, gadoquatrane 0.03 mmol Gd/kg is the same compound as BAY1747846. BAY1747846 is Bayer's internal code for gadoquatrane, and the 0.03 mmol Gd/kg designation refers to the gadolinium dose level used in the Phase 1 study. Both names refer to the same investigational MRI contrast agent.